NanoSphere Health Sciences’ Brand Evolve Formulas Expanding Rapidly Across Colorado and Beyond

Ryan Allway

July 11th, 2018

News

Next-Generation Cannabis Products Now Available in Over 200 Colorado Dispensaries, with Production Beginning in the California Market

DENVER, July 11, 2018 /CNW/ — NanoSphere Health Sciences, INC (CSE: NSHS) (OTC: NSHSF), the biotech firm behind the groundbreaking NanoSphere Delivery System™, is experiencing a period of rapid growth for its cannabis brand, Evolve Formulas. The company has not only successfully expanded the product line to over 200 dispensaries in the Colorado market, but has also officially begun training and preparation for production in the California market.

Propelling this accelerated growth is Evolve Formulas’ pioneering product, Transdermal NanoSerum™; a viscous gel which is applied to the skin for rapid and effective relief from pain, inflammation and anxiety. The rate of growth has been shown to be roughly 30% month over month in demand for NanoSerum™, allowing NanoSphere Health Sciences to discuss significant sales revenues for the first time since becoming publicly listed in December 2017.

Evolve Formulas products utilize the patented NanoSphere Delivery System™ to nanoencapsulate cannabinoids in lipid membranes for transportation through the skin and mucosa into the cells and bloodstream. This technology eliminates delayed onset of action, vastly increases bioavailability of the ingredients and alleviates adverse side effects of cannabis.

The NanoSphere Health Sciences business model is centered on licensing IP to allow the expansion of Evolve Formulas into new legal markets. Having recently announced a licensing partnership with Vertical™, the largest fully integrated company in the U.S. cannabis market, for multiple states, NanoSphere Health Sciences has now initiated partner training in California for the production of its products and unique technology and has started transporting essential equipment to new manufacturing sites.

“We are now in roughly one of every four stores in Colorado—an impressive rate of penetration into a highly competitive market. This, coupled with countless powerful testimonials we have received from Evolve Formulas customers—who rely on our products to relieve everything from chronic pain to PTSD—demonstrates our company’s superior offerings. We are also excited to be officially in the first stage of our Californiajourney by commencing production in this new market, so that we can bring the benefits of cannabis to even more consumers in a safer, more effective way,” said David Sutton, COO and President of NanoSphere Health Sciences and Evolve Formulas.

A full list of dispensaries in Colorado carrying Evolve Formulas products can be found here.

For more information or to schedule an interview, please contact Emily Kielthy at media@nanospherehealth.com or 646-695-7045.

On behalf of the Board

David Sutton, President and COO
720.520.4283
dsutton@nanospherehealth.com

Investor Contact:

Victor Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail: vgoncalves@nanospherehealth.com

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world’s first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

For more information contact:
Emily Kielthy
media@nanospherehealth.com
646-695-7045

View original content with multimedia:http://www.prnewswire.com/news-releases/nanosphere-health-sciences-brand-evolve-formulas-expanding-rapidly-across-colorado-and-beyond-300679394.html

SOURCE NanoSphere Health Sciences INC

View original content with multimedia: http://www.newswire.ca/en/releases/archive/July2018/11/c7696.html

Source: Canada Newswire (July 11, 2018 – 9:52 AM EDT)

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Search CannabisFN

Press Coverage

Psychedelics Index

Visit the CFN Video Library

Join Our Facebook Page

Top Videos

Alan Brochstein of 420 Investor

Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.

Matt Hawkins of Cresco Capital Partners

Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]

Aleafia Health Inc.

Aleafia, a vertically integrated, national cannabis company, operates major medical clinic, cannabis cultivation and R&D facilities.

The Green Organic Dutchman

The Green Organic Dutchman Holdings Ltd. is a premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe and Latin America and the Canadian adult-use market. The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, […]

Network Partners

Follow Us on Social Media

Facebook

Twitter

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.